Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 1.00 |
| ▸ | C1R | P00736 | 3/20 | 0.67 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.55 |
| ▸ | KLK7 | P49862 | 4/20 | 0.53 |
| ▸ | KLK14 | Q9P0G3 | 4/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.53 |
| ▸ | CTSG | P08311 | 3/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5921024 | 0.86 | ELANE (0.76) | ELANEC1RPBRM1 | |
| SCHEMBL914656 | 0.86 | ELANE (0.76) | ELANEC1RKLK7KLK14KLK5 | |
| SCHEMBL9984780 | 0.85 | ELANE (1.00) | ELANEC1RPBRM1KLK7KLK14 | |
| SCHEMBL17554099 | 0.85 | ELANE (0.73) | ELANEC1RKLK7KLK14KLK5 | |
| SCHEMBL9984683 | 0.83 | ELANE (1.00) | ELANEC1RPBRM1 | |
| SCHEMBL914707 | 0.81 | ELANE (0.67) | ELANEC1RKLK7KLK14KLK5 | |
| SCHEMBL9984776 | 0.80 | ELANE (1.00) | ELANEC1RPBRM1 | |
| SCHEMBL4190607 | 0.80 | ELANE (0.79) | ELANEC1RPBRM1KLK7KLK14 | |
| SCHEMBL9985824 | 0.80 | ELANE (1.00) | ELANEC1RPBRM1KLK7KLK14 | |
| SCHEMBL29574035 | 0.80 | ELANE (1.00) | ELANEC1RPBRM1KLK7KLK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319611-A1 | BENZOXAZINONE COMPOUND, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CHANG GUNG UNIVERSITY (TW) | 2011-12-29 | — | — | US | claimed |
| US-10201536-B2 | Methods and pharmaceutical compositions for the treatment of bacterial infections in patients suffering from cirrhosis | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-12 | — | — | US | disclosed |
| US-20180140597-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2018-05-24 | — | — | US | disclosed |
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | disclosed |
| US-20110319611-A1 | BENZOXAZINONE COMPOUND, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CHANG GUNG UNIVERSITY (TW) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201536-B2 | Methods and pharmaceutical compositions for the treatment of bacterial infections in patients suffering from cirrhosis | TLR8, TLR7, TLR3 | ELANE 99/4885C1R 2352/4885PBRM1 2577/4885 |
| US-20180140597-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS | TLR8, TLR7, TLR3 | ELANE 99/4885C1R 2352/4885PBRM1 2577/4885 |
| US-20110319611-A1 | BENZOXAZINONE COMPOUND, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CYP4X1, CYP2B6, CYP2C19 | ELANE 3461/4885C1R 84/4885PBRM1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.